Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Cancers × Sorafenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 196 Carcinoma, Renal Cell 69 Liver Neoplasms 59 Neoplasms 44 Leukemia, Myeloid, Acute 34 Neoplasm Metastasis 30 Carcinoma, Non-Small-Cell Lung 27 Breast Neoplasms 27 Melanoma 22 Kidney Neoplasms 19 Pancreatic Neoplasms 15 Sarcoma 14 Prostatic Neoplasms 13 Lung Neoplasms 13 Brain Neoplasms 12 Recurrence 11 Thyroid Neoplasms 10 Glioblastoma 10 Colorectal Neoplasms 10 Carcinoma 10 Precursor Cell Lymphoblastic Leukemia-Lymphoma 8 Myelodysplastic Syndromes 8 Multiple Myeloma 8 Urinary Bladder Neoplasms 6 Unspecified Adult Solid Tumor, Protocol Specific 6 Stomach Neoplasms 6 Rectal Neoplasms 6 Leukemia, Lymphocytic, Chronic, B-Cell 6 Ovarian Neoplasms 5 Liver Diseases 5

Interventions

Surveys and Questionnaires 5 pazopanib 3 Erlotinib Hydrochloride 3 Cetuximab 3 Vorinostat 2 Oxaliplatin 2 Bevacizumab 2 Azacitidine 2 satraplatin 1 ridaforolimus 1 ixazomib 1 X-Rays 1 Videotape Recording 1 Valproic Acid 1 Trastuzumab 1 Sugars 1 Sorafenib 1 Platinum 1 Pemetrexed 1 Magnetic Resonance Spectroscopy 1 Leucovorin 1 Lenalidomide 1 Lapatinib 1 LY 2275796 1 Injections, Subcutaneous 1 Fluorouracil 1 Everolimus 1 Curcumin 1 Crizotinib 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01608139 2012-10-19

Study of Curcumin, Vorinostat, and Sorafenib

M.D. Anderson Cancer Center

Phase 1 Withdrawn

Advanced Cancers

Data powered by HemOnc (CC BY 4.0) Colophon ⚡